Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 3,000
- Avg volume
- 4,346
- Day's range
- $0.07 – $0.07
- Shares out
- —
- Stochastic %K
- 52%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Res...
Show more
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 778 819 0244
- Website
- https://www.restartlife.co
- Address
- 700-838 West Hasting Street, Vancouver, Canada
Latest news
No headlines yet.
